BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 18593951)

  • 1. A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer.
    Bonome T; Levine DA; Shih J; Randonovich M; Pise-Masison CA; Bogomolniy F; Ozbun L; Brady J; Barrett JC; Boyd J; Birrer MJ
    Cancer Res; 2008 Jul; 68(13):5478-86. PubMed ID: 18593951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early postoperative CT as a prognostic biomarker in patients with advanced ovarian, tubal, and primary peritoneal cancer deemed optimally debulked at primary cytoreductive surgery.
    Lakhman Y; Akin O; Sohn MJ; Zheng J; Moskowitz CS; Iyer RB; Barakat RR; Sabbatini PJ; Chi DS; Hricak H
    AJR Am J Roentgenol; 2012 Jun; 198(6):1453-9. PubMed ID: 22623562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway.
    Yoshihara K; Tsunoda T; Shigemizu D; Fujiwara H; Hatae M; Fujiwara H; Masuzaki H; Katabuchi H; Kawakami Y; Okamoto A; Nogawa T; Matsumura N; Udagawa Y; Saito T; Itamochi H; Takano M; Miyagi E; Sudo T; Ushijima K; Iwase H; Seki H; Terao Y; Enomoto T; Mikami M; Akazawa K; Tsuda H; Moriya T; Tajima A; Inoue I; Tanaka K;
    Clin Cancer Res; 2012 Mar; 18(5):1374-85. PubMed ID: 22241791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microarray-based oncogenic pathway profiling in advanced serous papillary ovarian carcinoma.
    Trinh XB; Tjalma WA; Dirix LY; Vermeulen PB; Peeters DJ; Bachvarov D; Plante M; Berns EM; Helleman J; Van Laere SJ; van Dam PA
    PLoS One; 2011; 6(7):e22469. PubMed ID: 21799864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does systematic lymphadenectomy have a benefit on survival of suboptimally debulked patients with stage III ovarian carcinoma? A DEGOG* Study.
    Saygili U; Guclu S; Uslu T; Erten O; Ture S; Demir N
    J Surg Oncol; 2002 Nov; 81(3):132-7. PubMed ID: 12407725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression profiles as prognostic markers in women with ovarian cancer.
    Jochumsen KM; Tan Q; Høgdall EV; Høgdall C; Kjaer SK; Blaakaer J; Kruse TA; Mogensen O
    Int J Gynecol Cancer; 2009 Oct; 19(7):1205-13. PubMed ID: 19823056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study.
    Farley J; Smith LM; Darcy KM; Sobel E; O'Connor D; Henderson B; Morrison LE; Birrer MJ;
    Cancer Res; 2003 Mar; 63(6):1235-41. PubMed ID: 12649182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bowel resection at the time of primary debulking for epithelial ovarian carcinoma: outcomes in patients treated with platinum and taxane-based chemotherapy.
    Estes JM; Leath CA; Straughn JM; Rocconi RP; Kirby TO; Huh WK; Barnes MN
    J Am Coll Surg; 2006 Oct; 203(4):527-32. PubMed ID: 17000397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy.
    Santin AD; Zhan F; Bellone S; Palmieri M; Cane S; Bignotti E; Anfossi S; Gokden M; Dunn D; Roman JJ; O'Brien TJ; Tian E; Cannon MJ; Shaughnessy J; Pecorelli S
    Int J Cancer; 2004 Oct; 112(1):14-25. PubMed ID: 15305371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome.
    Manning-Geist BL; Hicks-Courant K; Gockley AA; Clark RM; Del Carmen MG; Growdon WB; Horowitz NS; Berkowitz RS; Muto MG; Worley MJ
    Am J Obstet Gynecol; 2019 Oct; 221(4):326.e1-326.e7. PubMed ID: 31082382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression signature with independent prognostic significance in epithelial ovarian cancer.
    Spentzos D; Levine DA; Ramoni MF; Joseph M; Gu X; Boyd J; Libermann TA; Cannistra SA
    J Clin Oncol; 2004 Dec; 22(23):4700-10. PubMed ID: 15505275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel risk score system for assessment of ovarian cancer based on co-expression network analysis and expression level of five lncRNAs.
    Zhao Q; Fan C
    BMC Med Genet; 2019 Jun; 20(1):103. PubMed ID: 31182053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stem cell-like gene expression in ovarian cancer predicts type II subtype and prognosis.
    Schwede M; Spentzos D; Bentink S; Hofmann O; Haibe-Kains B; Harrington D; Quackenbush J; Culhane AC
    PLoS One; 2013; 8(3):e57799. PubMed ID: 23536770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of an energy metabolism‑related gene signature in ovarian cancer prognosis.
    Wang L; Li X
    Oncol Rep; 2020 Jun; 43(6):1755-1770. PubMed ID: 32186777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of an immune gene-set based Prognostic signature in ovarian cancer.
    Shen S; Wang G; Zhang R; Zhao Y; Yu H; Wei Y; Chen F
    EBioMedicine; 2019 Feb; 40():318-326. PubMed ID: 30594555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stage IV ovarian cancer: impact of surgical debulking.
    Curtin JP; Malik R; Venkatraman ES; Barakat RR; Hoskins WJ
    Gynecol Oncol; 1997 Jan; 64(1):9-12. PubMed ID: 8995540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer.
    Wu C; He L; Wei Q; Li Q; Jiang L; Zhao L; Wang C; Li J; Wei M
    Cancer Med; 2020 Feb; 9(3):1242-1253. PubMed ID: 31856408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma.
    Guo W; Zhu L; Yu M; Zhu R; Chen Q; Wang Q
    Clin Epigenetics; 2018 Nov; 10(1):142. PubMed ID: 30446011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis.
    Liu N; Chen NY; Cui RX; Li WF; Li Y; Wei RR; Zhang MY; Sun Y; Huang BJ; Chen M; He QM; Jiang N; Chen L; Cho WC; Yun JP; Zeng J; Liu LZ; Li L; Guo Y; Wang HY; Ma J
    Lancet Oncol; 2012 Jun; 13(6):633-41. PubMed ID: 22560814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of Optimal Cytoreductive Surgery of Serous Ovarian Cancer With Gene Expression Data.
    Abdallah R; Chon HS; Bou Zgheib N; Marchion DC; Wenham RM; Lancaster JM; Gonzalez-Bosquet J
    Int J Gynecol Cancer; 2015 Jul; 25(6):1000-9. PubMed ID: 26098088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.